Targeted immunotherapy strategies in ANCA-associated vasculitis - 01/05/19
pages | 6 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | The advent of targeted immunotherapy is radically changing the management of ANCA-associated vasculitis. |
• | Rituximab is not less effective than cyclophosphamide and has been validated for the induction treatment of granulomatosis with polyangiitis and severe microscopic polyangiitis. |
• | Rituximab is particularly useful in patients with refractory or relapsing disease, in women of childbearing potential, and in patients previously treated with cyclophosphamide. |
• | Remission maintenance therapy is indispensable. Rituximab has been proven superior over conventional immunosuppressant therapy for remission maintenance. |
• | In eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome), maintenance therapy with the IL-5-antagonist mepolizumab is effective in decreasing the glucocorticoid requirements and alleviating the asthma and sinonasal symptoms. Its efficacy on the vasculitis is less clear. |
Abstract |
Targeted immunotherapy is substantially improving the management of ANCA-associated vasculitides (AAV), which include granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg–Strauss syndrome). This article reviews the current role for targeted immunotherapy in AAV, its validated indications, and avenues for further development. Rituximab is a validated induction treatment for GPA and severe MPA. Rituximab in these indications is not less effective than cyclophosphamide and is particularly useful in patients with refractory or relapsing disease, women of childbearing potential, and patients previously treated with cyclophosphamide. Rituximab is more effective than cyclophosphamide for treating relapses. For remission maintenance therapy, which is indispensable, rituximab has been proven superior over conventional immunosuppressive treatment. Rituximab is licensed in the USA and in Europe for the induction treatment of severe forms of GPA and MPA. An extension study for remission maintenance therapy is ongoing. In EGPA, although maintenance treatment with the interleukin-5 antagonist mepolizumab is effective in decreasing glucocorticoid requirements and in alleviating asthma and sinonasal symptoms, its efficacy on the vasculitis remains somewhat unclear. Mepolizumab is licensed for use in EGPA, and rituximab is also being evaluated as an induction and maintenance agent. Immunoglobulins can be helpful as an adjuvant treatment for active AAV with severe immunedepression, notably when infections occur. Plasma exchange is indicated in AAV with advanced renal dysfunction and, perhaps, in the event of alveolar hemorrhage, a possibility that will be assessed in 2018 in a large international study.
Le texte complet de cet article est disponible en PDF.Keywords : Therapeutic immunomodulation, Necrotizing vasculitis, Granulomatosis with polyangiitis, Eosinophilic granulomatosis with polyangiitis, Biological agents, Rituximab
Plan
Vol 86 - N° 3
P. 321-326 - mai 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?